15-letniy opyt ispol'zovaniya Gertseptina pri HER2-pozitivnom rake molochnoy zhelezy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Herceptin appeared in clinical practice for more than 15 years ago and firmly took the leading position in the treatment of HER2-positive breast cancer, changing our ideas about the course of this aggressive disease. During the whole period of application of this drug, indications for its use have increased considerably: today Herceptin is used successfully in the treatment of early and metastatic HER2-positive breast cancer; it is highly effective within a year in adjuvant therapy. A new dosage form of Herceptin for subcutaneous administration was recently registered. Numerous clinical studies have demonstrated the high efficacy of therapy with Herceptin in combination with other anticancer drugs. All of this determines high results of treatment of patients with HER2-positive breast cancer, increasing the duration of remission and cure rate of millions of patients worldwide.

全文:

受限制的访问

参考

  1. Kelley R.F., O'Connell M.P., Carter P., Presta L., Eigenbrot C., Covarrubias M., Snedecor B., Bourell J.H., Vetterlein D. Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. Biochemistry. 1992;31: 5434-41.
  2. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 2005;23:4265-74.
  3. Cobleigh M.A, Vogel C.L., TripathyD.,Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999;17:2639-48.
  4. Vogel C.L.,Cobleigh M.A.,Tripathy D.,Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002;20:719-26.
  5. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005;353:1659-72.
  6. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., Goldhirsch A., Untch M., Mariani G., Baselga J., Kaufmann M., Cameron D., Bell R., Bergh J., Coleman R., Wardley A., Harbeck N., Lopez R.I., Mallmann P., Gelmon K., Wilcken N., Wist E., Sanchez Rovira P., Piccart-Gebhart M.J. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36.
  7. Perez E.A, Romond E.H., Suman V.J., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 2011;29:3366-73.
  8. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005;353:1673-84.
  9. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., Wickerham D.L., Begovic M., DeCillis A., Robidoux A., Margolese R.G., Cruz A.B.Jr, Hoehn J.L., Lees A.W., Dimitrov N.V., Bear H.D. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 1998;16(8):2672-85
  10. Bear H.D., Anderson S., Smith R.E., Geyer C.E., Jr, Mamounas E.P., Fisher B., Brown A.M., Robidoux A., Margolese R., Kahlenberg M.S., Paik S., Soran A., Wickerham D.L., Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 2006;24(13):2019-27.
  11. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., Pusztai L., Green M.C., Arun B.K., Giordano S.H., Cristofanilli M., Frye D.K., Smith T.L., Hunt K.K., Singletary S.E., Sahin A.A., Ewer M.S., Buchholz T.A., Berry D., Hortobagyi G.N. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 2005;23(16):3676-85.
  12. Buzdar A.U., Valero V., Ibrahim N.K., Francis D., Broglio K.R., Theriault R.L., Pusztai L., Green M.C., Singletary S.E., Hunt K.K., Sahin A.A., Esteva F., Symmans W.F., Ewer M.S., Buchholz T.A., Hortobagyi G.N. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubi-cin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin. Cancer Res. 2007;13(1):228-33.
  13. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Climent M.A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P., Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377-84.
  14. von Minckwitz G.,Rezai M.,Loibl S.,Fasching P.A., Huober J., Tesch H., Bauerfeind I., Hilfrich J., Eidtmann H., Gerber B., Hanusch C., Kühn T., du Bois A., Blohmer J.U., Thomssen C., Dan Costa S., Jackisch C., Kaufmann M., Mehta K., Untch M. Capecitabine in addition to anthracyclineand taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J. Clin. Oncol.2010;28(12):2015-23.
  15. Untch M., Rezai M., Loibl S., Fasching P.A., Huober J., Tesch H., Bauerfeind I., Hilfrich J., Eidtmann H., Gerber B., Hanusch C., Kühn T., du Bois A., Blohmer J.U., Thomssen C., Dan Costa S., Jackisch C., Kaufmann M., Mehta K., von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J.Clin. Oncol. 2010;28(12):2024-31.
  16. Untch M., Fasching A. P., Konecny E.G., Hasmüller S., Lebeau A., Kreienberg R., Camara O., Müller V., du Bois A., Kühn T., Stickeler E., Harbeck N., Höss C., Kahlert S., Beck T., Fett W., Mehta K.M., von Minckwitz G., Loibl S. Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow up data of the TECHNO trial. J. Clin. Oncol. 2011;29(25):3351-57.
  17. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., Gomez H., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633-40.
  18. Guarneri V., Frassoldati A., Bottini A., Cagossi K., Bisagni G., Sarti S., Ravaioli A, Cavanna L., Giardina G., Musolino A., Untch M., Orlando L., Artioli F., Boni C., Generali D.G., Serra P., Bagnalasta M., Marini L., Piacentini F., DAmico R., Conte P. Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study. J. Clin. Oncol. 2012;30(16):1989-95.
  19. Bittner B., Richter W., Hourcade-Potelleret F., McIntyre C. Development of a subcutaneous formulation for trastuzumab - non-clinical and clinical bridging approach to the approved Intravenous dosing' regimen. Arzneimittelforschung. 2012;62:401-09.
  20. Pivot X., Gligorov J., Müller V., Curigliano G., Knoop A, Verma S., Jenkins V., Scotto N., Osborne S., Fallowfield L. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann. Oncol. 2014;25(10):1979-87.
  21. ScheuerW,FriessT,BurtscherH,BossenmaierB, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69:9330-36.
  22. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68: 878-87.
  23. Swain SM, Kim SB, Cortes J., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J.M., Schneeweiss A., Knott A., Clark E., Ross G., Benyunes M.C., Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive meta static breast cancer (CLEOPATRA study): overall survival results from a randomised, doubleblind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461-71.
  24. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., Lluch A., Staroslawska E., de la Haba-Rodriguez J., Im S.A., Pedrini J.L., Poirier B., Morandi P., Semiglazov V., Srimuninnimit V., Bianchi G., Szado T., Ratnayake J., Ross G., Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32.
  25. Widdison W.C., Wilhelm S.D., Cavanagh E.E., Whiteman K.R., Leece B.A., Kovtun Y., Goldmacher V.S., Xie H., Steeves R.M., Lutz R.J., Zhao R., Wang L., Blattler W.A., Chari R. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 2006;49:4392-408.
  26. Krop I.E., Beeram M., Modi S., Jones S.F., Holden S.N., Yu W., Girish S., Tibbitts J., Yi J.H., Sliwkowski M.X., Jacobson F., Lutzker S.G., Burris H.A. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive meta static breast cancer. J. Clin. Oncol. 2010;28: 2698-704.
  27. Krop I.E., LoRusso P., Miller K.D., Modi S., Yardley D., Rodriguez G., Guardino E., Lu M., Zheng M., Girish S., Amler L., Winer E.P., Rugo H.S. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 2012;30:3234-41.
  28. Hurvitz S.A., Dirix L., Kocsis J., Bianchi G.V., Lu J., Vinholes J., Guardino E., Song C., Tong B., Ng V., Chu Y.W., Perez E.A. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin Oncol. 2013; 31:1157-63.
  29. Verma S., Miles D, Gianni L., Krop I.E., Welslau M., Baselga J., Pegram M., Oh D.Y., Dieras V., Guardino E., Fang L., Lu M.W., Olsen S., Blackwell K. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-91.
  30. Давыдов М.И., Аксель М.Е. Статистика злокачественных новообразований в России и СНГ в 2012 г. М., 2014.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##